Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Invesco Ltd.

Invesco Ltd. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 508,069 shares of the specialty pharmaceutical company's stock after buying an additional 22,027 shares during the period. Invesco Ltd. owned approximately 0.92% of Supernus Pharmaceuticals worth $18,372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC lifted its holdings in Supernus Pharmaceuticals by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after buying an additional 28,517 shares during the period. American Century Companies Inc. lifted its stake in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after acquiring an additional 40,968 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock worth $14,449,000 after purchasing an additional 27,134 shares in the last quarter.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently commented on SUPN. Cantor Fitzgerald reiterated a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th.

Supernus Pharmaceuticals Stock Down 0.5 %

SUPN stock traded down $0.14 during mid-day trading on Wednesday, hitting $30.70. 226,899 shares of the company were exchanged, compared to its average volume of 493,134. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.71 billion, a P/E ratio of 28.71 and a beta of 0.90. The business has a fifty day simple moving average of $32.41 and a 200-day simple moving average of $35.01.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.